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Zusammenfassung 
 
Amylin reduziert die Grösse einer Mahlzeit über die Area Postrema (AP) und 
peripher appliziert führt es zu einer cFos-Expression in AP Neuronen. 
Ungefähr 50% dieser Neurone sind noradrenerg und scheinen Amylin’s 
anorektische Wirkung zu vermitteln. Salmon calcitonin (sCT) ist ein Amylin 
Agonist und wirkt stark anorektisch, wobei die vermittelnden Neurone nicht 
bekannt sind. Männliche Wistar Ratten erhielten eine AP-(APX) oder Schein-
Läsion (sham). Mahlzeitenmuster wurden unter ad libitum Bedingungen und 
nach einer Fastenperiode analysiert. Die Rolle der AP bei der anorektischen 
Wirkung von sCT im Vergleich zu Amylin wurde bei APX und sham Ratten 
anhand Fütterungsstudien und der Expression von cFos ermittelt. Der 
Phänotyp der cFos exprimierenden Neurone wurde mittels Mehrfachfärbung 
gegen cFos und  Dopamin-β-Hydroxylase (DBH) oder Tryptophan 
Hydroxylase (TPH) untersucht. Um einen Unterschied bei dem glutaminergen 
Input festzustellen, wurde die VGLUT2 Apposition zu Amylin- und sCT 
aktivierten Neuronen bestimmt. Ähnlich wie bei Amylin, ist eine intakte AP die 
Voraussetzung für die anorektische Wirkung von sCT und die Ko-Expression 
von cFos und DBH war auch ähnlich. Die Ko-Expression von cFos und TPH 
war jedoch vernachlässigbar klein. Wir konnten keine Unterschiede beim 
glutaminergen Input finden nach Amylin und sCT Behandlung . Unsere Studie 
konnte aufzeigen, dass Amylin und sCT ähnliche Neurone aktivieren und 
diese vorwiegend in der AP liegen. 
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Summary 
 
Amylin reduces meal size via the area postrema (AP). Peripheral amylin leads 
to the expression of cFos protein in AP neurons; approximately 50% of these 
neurons are noradrenergic and appear to mediate amylin’s anorectic action. 
Salmon calcitonin (sCT) is an amylin agonist that potently reduces eating but 
the neurons involved are unknown. 
We compared sCT- and amylin-activated hindbrain pathways and the role of 
the AP. Male Wistar rats underwent surgical lesion of the AP (APX) or sham 
surgery. Meal patterns were analyzed under ad libitum and post-deprivation 
conditions. The role of the AP in mediating sCT's anorectic action was 
examined in feeding experiments and the cFos expression was compared 
between surgery groups, and relative to amylin. The phenotype of cFos-
expressing neurons was examined by testing for the co-expression of 
dopamine-β-hydroxylase (DBH) or tryptophan hydroxylase (TPH). By 
measuring the apposition of VGLUT2-positive boutons, potential glutaminergic 
input to amylin- and sCT-activated AP neurons was compared. An intact AP 
was necessary for sCT to reduce eating. Co-expression between cFos 
activation and DBH after amylin or sCT did not differ markedly. Colocalization 
of cFos and TPH was minor. Approximately 95% of neurons expressing cFos 
and DBH after amylin or sCT treatment were apposed to VGLUT2-positive 
boutons. We suggest that the hindbrain pathways engaged by amylin and 
sCT share many similarities, including the mediation by AP neurons. 
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Introduction 
 
Amylin and calcitonin are structurally and functionally related peptides of the 
calcitonin-like gene peptide superfamily (Wimalawansa, 1997). Amylin and 
calcitonin share a common core receptor, the calcitonin receptor, which is 
transformed into a specific amylin receptor by receptor activity modifying 
proteins (Sexton et al., 1994; Christopoulos et al., 1999; Muff et al., 1999). 
Amylin is co-secreted with insulin from pancreatic β-cells (Butler et al., 1990; 
Ogawa et al., 1990) and one physiological response that amylin and calcitonin 
share is the inhibition of eating (Lutz et al., 2000). While the anorectic action 
of mammalian calcitonin is relatively weak, fish-derived calcitonin, like salmon 
calcitonin (sCT), has often been used in pharmacological studies aimed at 
identifying amylin’s mechanism of action (Lutz et al., 2000). In contrast to 
amylin, sCT displays stronger, irreversible receptor binding, which translates 
into a more potent, longer-lasting eating-inhibitory response (Riediger et al., 
1999; Lutz et al., 2000; Reidelberger et al., 2002). 
 
Strong evidence suggests that the area postrema (AP) is an important brain 
site mediating amylin’s anorectic effect (Lutz, 2012). Lesions of the AP and its 
amylin receptor population abolish peripheral amylin’s eating-inhibitory effects 
(Lutz et al., 1998; Lutz et al., 2001; Mack et al., 2010). Administration of 
exogenous peripheral amylin induces a strong cFos response in the AP and in 
several downstream nuclei, including the nucleus of the solitary tract (NTS; 
Rowland et al., 1997; Rowland & Richmond, 1999; Barth et al., 2004; Riediger 
et al., 2004). The neurochemical phenotypes of the neurons mediating 
amylin’s and sCT’s inhibitory effect on eating are only partially identified. 
Approximately 50% of amylin-activated cells expressing cFos protein within 
the AP were also positive for the specific noradrenergic marker, dopamine-
beta-hydroxylase (DBH; Potes et al., 2010). These DBH-positive neurons 
seem to be functionally relevant, because ablating them with saporin toxin 
reduced amylin’s anorectic action (Potes et al., 2010). It is unknown which 
neuronal populations are specifically activated by sCT, and whether sCT also 
activates the same noradrenergic population as amylin.  
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More generally, ablating the AP not only prevents amylin’s anorectic effect but 
also alters physiological feedback mechanisms that lead to a disruption in 
meal patterns (Ritter & Edwards, 1984; Stricker et al., 1997). Hence, to further 
probe the role of the AP in respect to food intake control and meal patterns, 
we first aimed to analyze meal patterns in our rat model of AP lesions, 
compared to sham lesioned rats. Our second goal was to determine whether 
equipotent doses of amylin and sCT activate phenotypically similar neuronal 
populations in the AP. To this end, we assessed whether the cFos expression 
colocalizes with markers for catecholaminergic and serotoninergic neurons 
following amylin or sCT administration. Finally, because glutamatergic 
transmission may underlie several effects mediated by noradrenergic AP 
neurons (Stornetta et al., 2002), and because this may be relevant for amylin-
induced activation of the AP (Fukuda et al., 2013), we evaluated the 
apposition of vesicular glutamate transporter-2 (VGLUT2)-positive boutons to 
neurons co-expressing cFos and DBH in the AP after amylin or sCT. 
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Materials and Methods 
 
Animals. Male Wistar rats (200-250 g; Charles River, Sulzfeld, Germany) 
were maintained at a constant ambient temperature (21 ± 1°C) under an 
artificial 12 h light/dark cycle with food and water available ad libitum, unless 
noted otherwise. Rats were fed a standard chow diet (no. 3430, Provimi Kliba, 
Gossau, Switzerland) during the experiments. All experiments were 
performed with the approval of the Veterinary Office of the Canton Zurich, 
Switzerland, and in accordance with the EU Directive 2010/63/EU on the 
protection of animals used for scientific purposes. 
 
Drugs. Salmon calcitonin and amylin (Bachem AG, Bubendorf, Switzerland; 
catalogue numbers: amylin H-9475.1000, sCT H-2260.0001) were 
reconstituted with saline and diluted with saline to final doses of 1, 5 or 10 
µg/kg, with an injection volume of 1 ml/kg. 
 
Surgery. Rats were anesthetized (IP) using a mixture of ketamine (50 mg/kg, 
Narketan, Vétoquinol AG, Ittingen, Switzerland), xylazine (2.5 mg/kg, Xylazin, 
Streuli Pharma AG, Uznach, Switzerland), and acepromazine (0.75 mg/kg, 
Prequillan, Arovet AG, Dietikon, Switzerland). The head of the rat was flexed 
ventrally at an approximate 110-degree-angle in a stereotaxic frame. Skin and 
three layers of neck musculature were cut and retracted for visualization of 
the foramen magnum. Under visual control with a surgical microscope, the 
cranial dura mater was penetrated with an angled cannula tip and the CSF 
was blotted. AP lesions were performed by aspirating the AP with a blunted 
cannula tip fixed to a flexible tube attached to a vacuum pump (Lutz et al., 
1998; Jordi et al., 2013). In sham-lesioned rats, the AP was exposed but not 
touched. Musculature and skin were sutured respecting the individual muscle 
layers. Rats received SC injections of 5 ml sterile saline, antibiotics (7.5 mg/kg 
enrofloxacin, Baytril 2.5%, Provet AG, Lyssach, Switzerland) and an analgesic 
(1 mg/kg flunixin, Fluniximin, Graeub AG, Bern, Switerland) daily for at least 
three days post surgery, and were given 1 to 2 weeks to recover from the 
surgery. At the end of the experiments AP lesions were confirmed 
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histologically (Lutz et al., 1998; Lutz et al., 2001; Riediger et al., 2004), in 
parallel with the immunohistochemical quantification. 
 
Experiment 1: Meal pattern analysis in untreated AP-lesioned and sham-
lesioned rats. Meal patterns in sham- and AP-lesioned groups (n= 16 and 13, 
respectively) were analysed using the BioDAQ Food Intake Monitor 
(Research Diets Inc., New Brunswick, NJ). The technical specifications of the 
monitoring system have been described previously (Boyle et al., 2011). Rats 
were habituated to a 12-h fast twice per week followed by 3 days of 
adaptation to the BioDAQ cages (type 2000P, Tecniplast, Germany). Meal 
pattern data were collected and analyzed under two conditions. First, eating 
was recorded for 24h in ad libitum-fed rats. Second, 24-h food intake data 
were collected after a 12-h fast during the light phase. Meal pattern data 
collected from each rat were segmented into meals by clustering independent 
feeding bouts. The criteria defining a meal were a minimum inter-meal interval 
of 15 min and a minimum meal size of 0.23 g. Data were analyzed using the 
BioDAQ Monitoring software. 
 
Experiment 2: Behavioral experiments; Dose response study and 
identification of equipotent eating-inhibitory doses of amylin and sCT. 
 Sham- and AP-lesioned rats were individually housed in hanging wire mesh 
cages (Indulab AG, Gams, Switzerland, stainless steel, 47x33x20 cm) fitted 
with external food hoppers. Twice per week, rats were fasted for 12 h during 
the light phase. Shortly before dark onset rats were injected IP with saline, 
amylin or sCT; at dark onset, food was given back. Food intake was 
measured manually using a digital scale after 1, 2, 4 and 24 h. Tests were 
repeated in a randomized, crossover manner, so that each animal within the 
surgery group was examined under all conditions. The dose-response 
relationships for amylin and sCT were assessed using three increasing doses 
(1, 5, 10 µg/kg). Based on these findings equipotent doses of amylin (10 
µg/kg) and sCT (5 µg/kg) were used in a second behavioral experiment. 
 
Experiments 3, 4 and 5: Phenotypic characterization of amylin- and sCT-
activated neurons: Rats were fasted for 12 h during the light phase before 
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receiving injections of saline, amylin (10 µg/kg) or sCT (5 µg/kg) at dark onset. 
Food was withheld and 90 min later, rats were deeply anesthetized with 
pentobarbital (100 mg/kg, IP, Cantonal Pharmacy of Zurich, Switzerland), 
transcardially perfused with 4% paraformaldehyde in 0.1 M phosphate buffer 
(PB), and brains collected. 
 
Perfused brains were kept in 4% paraformaldehyde for 48 h, followed by 
cryoprotection in 0.1 M PB (pH: 7.2) containing 20% sucrose for 24 h. Brains 
where then frozen with hexane (Sigma Aldrich) on dry ice. Six series of 30-µm 
thick frontal sections (from Bregma -6.36mm to -14.40mm) were cut on a 
cryostat (Leica microsystems, Wetzlar, Germany). The sections were kept in a 
cryoprotecting medium (50% 0.1 M PB, 30% ethylene glycol, 20% glycerol) at 
-20 °C until processing for immunohistochemistry. One series of sections from 
each brain was processed for the detection of cFos and DBH, one series for 
the detection of cFos and TPH, and one series was processed for the 
detection of cFos, DBH and VGLUT2.  
 
Experiment 3: Double staining for cFos and Dopamine-β-Hydroxylase.  All 
rinses were conducted in 0.1 M PB for 10 min. At least four rinses were 
implemented between every incubation step. Free-floating sections were 
incubated for 1 hour at room temperature in a blocking solution of 0.1 M PB 
containing 1% normal donkey or normal goat serum (NDS or NGS) and 0.3% 
Triton-X (Triton, X-100, Sigma Aldrich, Germany). The primary and secondary 
antibodies were diluted in 0.1 M PB containing 1% NDS or NGS and 0.3% 
Triton-X at concentrations described in Table 1. Sections were incubated in 
the two primary antibody solutions for subsequent overnights (beginning with 
the cFos antibody) at room temperature, followed by 1-h incubation in 
fluorochrome-conjugated secondary antibody solutions at room temperature. 
Stained sections were mounted on gelatinized slides and cover slipped with 
Citifluor (AF-100, Citifluor LTD, London, UK). 
 
Experiment 4: Double staining for cFos and Tryptophan Hydroxylase. All 
rinses were conducted in 0.1 M PB for 10 min. At least 4 rinses were 
implemented between every incubation step. Free-floating sections were 
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blocked for 1 h at room temperature in 0.1 M PB containing 1% NDS and 
0.3% Triton-X (Sigma Aldrich). Sections were incubated overnight at room 
temperature in the anti-cFos primary antibody diluted in 0.1 M PB, 1% NDS 
and 0.3% Triton-X. Thereafter, sections were incubated in the corresponding 
secondary antibody (see Table 1) diluted in 0.1 M PB, 1% NDS and 0.3% 
Triton-X for 1 h at room temperature. After the incubation with the secondary 
antibody, the tissue was incubated for 1 h at room temperature in the ABC 
solution.  For visualization of cFos-positive cells, sections were incubated in 
enhanced 3,3’-diaminobenzidine-tetrahydrochloride (DAB) chromogen 
solution (0.05% DAB, 0.04% nickel, 0.08% cobalt, and 0.3% H2O2 in PBS) for 
approximately 2 to 5 min. Next, the tissue was incubated in the anti-TPH 
primary antibody overnight at room temperature and the following day, in the 
corresponding secondary antibody for 1 h. To visualize TPH-positive cells, a 
peroxidase substrate system (ImmPACT NovaRED, Vector Laboratories, 
Burlingame, CA) was used. The sections were incubated in the peroxidase 
substrate for 2 to 5 min, and then rinsed in distilled water to stop the staining 
process and wash off the remaining reagents. All concentrations of antibody 
and chromogen solutions are shown in Table 1. Tissue was mounted on 
gelatinized slides and left to air dry for up to 1 h. Slides were then dehydrated 
in an ascending series of clean alcohols, defatted in xylol, and cover slipped 
with a DPX medium (Fisher Scientific, Reinach, Switzerland). 
 
Quantification and analysis of double immunolabeling.  Photomicrographs of 
all sections containing AP, subpostremal NTS, NTS, dorsal and central raphe 
nuclei (DR, CR) were taken at 20x magnification and a numeric aperture of 
0.5, using a light microscope (Zeiss Imager Z2) fitted with a black and white 
camera (Zeiss Axiocam HRm) or a color camera (Zeiss Axiocam). cFos-
positive cells were counted using ImageJ software (National Institutes of 
Health, Bethesda, MD). All quantifications were done manually in a blinded 
manner, counting by eye using the digital images. Sections within the 
following bregma distances were quantified: -13.56 to -14.40 mm for the AP, -
11.76 to – 14.40 mm for the NTS, -6.36 to -9.36 mm for the DR and CR. For 
each animal, the counts from all sections (corresponding to a particular brain 
area) were averaged. Final results are reported as group means ± SEM. For 
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the remainder of this manuscript this method of light microscopical manual 
counting quantification, will be referred to as LM. 
 
Experiment 5: Triple staining for cFos, Dopamine-β-Hydroxylase and 
Vesicular Glutamate Transporter-2. Rinses were conducted as above. All 
incubation and blocking steps were conducted at room temperature. Free-
floating sections were first blocked in sequential blocking solutions consisting 
of 0.1M PB and Avidin (1:10) or Biotin (1:10), for 15 minutes each, followed by 
blocking in 0.3% Triton-X and 1% NDS in 0.1M PB for 1 hour. Sections were 
then incubated overnight in a 0.1M PB solution containing 0.3% Triton-X, 1% 
NDS, and all three primary antibodies (anti-cFos, -DBH and -VGLUT2). On 
the following day, sections were incubated for 1 hour in a solution of 0.1M PB 
containing 0.3% Triton-X, 1% NDS and all three fluorochrome-conjugated 
secondary antibodies (see Table 1). Stained sections were then mounted on 
gelatinized slides and cover slipped with Citifluor. 
 
Quantification and analysis of triple immunolabeling. All brain sections 
containing the AP were scanned with a CLSM Leica SP5 Mid UV-VIS 
confocal microscope equipped with an x-y-z motorized stage and lasers 
appropriate for detecting Cy3, Alexa 488 and Alexa 647 fluorescence. Scans 
were taken in the tile mode using a 63x magnification and a numeric aperture 
(oil immersion) of 1.4. The extent of the AP was marked manually (x/y 
positions) and the software (LASF, advanced fluorescence lite, 2.6.0, Leica 
microsystems, Wetzlar, Germany) adjusted the total number of tiles to be 
scanned. At three randomly chosen x/y coordinates in each section, the 
thickness of the section was measured manually and then used to define the 
z-height of all tiles to be scanned at z-increments of 0.5 µm. An overlap of 
15% was used for the subsequent stitching of the tiles to generate a complete 
3D image of the AP section. 
 
Using the Optical Fractionator (Stereo Investigator 10, MBF Bioscience, 
Williston, VT; as described previously by West et al., 1991), cFos-positive, 
DBH-positive, cFos and DBH double-positive cells and VGLUT2 positive 
boutons were counted using a counting frame size of 80 × 80 µm, a disector 
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height of 10 µm and a top guard zone of 2 µm. Only VGLUT2-positive 
boutons that were abutting a neuron’s soma were considered. All boutons in 
apposition to cFos and DBH double-positive cells selected by the Disector 
probes were counted. Unbiased estimates of the total number of neurons of 
interest per AP were acquired by multiplying the counts with the inverse of the 
sampling fractions for sections, area and section thickness. This method of 
confocal stereological quantification will be referred to as CM for the 
remainder of this manuscript. 
 
Statistics. Statistical analysis was done using Prism (Graph Pad Software, La 
Jolla, CA). One-way ANOVA and Student’s t- tests were used as appropriate. 
Bonferroni Post hoc analysis was performed when appropriate. A P-value of 
<0.05 was considered statistically significant for all experiments.  
 
Experiment 1: T-tests; Sham versus APX within ad-libitum and post-
deprivation conditions, n=13-17 per surgery group 
Experiment 2: One-way ANOVA; drug as main factor, within surgery (APX or 
sham) condition, n= 11-13 per surgery group 
Experiment 3: One-way ANOVA; drug as main factor, within surgery (APX or 
sham) condition, n= 13-17 per surgery group 
Experiment 4: One-way ANOVA; drug as main factor, within surgery (APX or 
sham) condition, n= 13-17 per surgery group 
Experiment 5: T-tests; amylin 10 µg/kg versus sCT 5 µg/kg within sham-
lesioned rats, n= 5-6 per treatment group 
Experiment 6: T-tests; comparison of quantitative analysis using CM versus 
LM within treatment condition (amylin 10 µg/kg or sCT 5 µg/kg), n= 5-6 per 
treatment group. 
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Results 
 
Experiment 1: Meal pattern analysis of sham and APX rats 
APX rats exhibited altered meal patterns indicative of a change in feedback 
inhibition of ingestive behavior. Under ad libitum conditions, the size of the 
first meal was significantly larger in APX than sham rats (t (26)=5.425, p < 
0.001), but APX rats took longer after dark onset to initiate the first meal (t 
(26)= 3.028, p =0.0055). Average meal size (t (26)= 3.870, p <0.001) as well 
as meal duration (t (26)= 2.192, p= 0.0375) were significantly increased in 
APX compared to sham rats. Additionally, sham rats ate more meals per day 
than APX rats (t (26)= 3.564, p=0.0014), but the inter-meal interval was not 
significantly different. Total 24-h food intake did not differ between sham and 
APX rats as illustrated in Table 2. 
 
In the post-deprivation condition following a 12-hour light phase fast, food 
intake of APX rats in the following 24 h was significantly reduced compared to 
sham (t (26)= 3.128, p = 0.0042).  Similar to ad libitum conditions, APX rats 
consumed significantly fewer meals (t (26)= 5.728, p <0.0001) and their 
latency to feed after dark onset was longer  (t (26)= 5.650, p <0.0001). 
Average meal size, meal duration, size of first meal and the inter-meal interval 
did not differ significantly between the two surgery groups in this state, which 
was largely attributed to a deprivation-induced increase in meal size in the 
sham group that was not observed in the APX group. 
 
Experiment 2.1: Dose response curve 
Amylin and sCT dose-dependently decreased eating in sham rats, as 
previously published (Figure 1A & C; Lutz et al., 2000). Eating was 
significantly decreased by 5 and 10 µg/kg amylin at the 1-h (F (3,12) = 7.034, 
p< 0.01) and by 10 µg/kg amylin at the 2-h time point (F (3,12) = 5.941, p< 
0.01). One µg/kg amylin had no effect on eating and none of the doses 
decreased eating at the 4-h time point (F (3,12) = 1.415, p> 0.05). Amylin did 
not decrease eating in APX rats at any dose or time point (F h-1, -2, -4 
(3,12)= 0.4145, 0.6527 and 0.9649 respectively, p> 0.05 for all; Figure 1B). 
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Compared to saline and 1 µg/kg, 5 and 10 µg/kg sCT reduced food intake at 
all times (F h-1, -2, -4, -24 (3,14)= 38.07, 40.16, 67.14 and 401.6 respectively, 
p< 0.001) in sham rats. Five and 10 µg/kg sCT doses were not significantly 
different from each other. One µg/kg decreased eating only at 4 and 24 h 
post-injection (F h-4, -24 (3,14)= 67.14 and 401.6 respectively, p< 0.05 and 
p<0.001). The AP lesion almost completely blocked the effect of sCT on 
eating. However, after receiving 5 or 10 µg/kg sCT, 24-h food intake in APX 
rats was significantly reduced, as shown by a one-way ANOVA and 
subsequent Bonferroni post-hoc analysis (h-4; F (3,13) = 3.545, p < 0.05; 
Figure 1D). 
 
Experiment 2.2: Equipotent doses of amylin and sCT 
Figure 2A shows the significant food intake reduction after amylin and sCT in 
sham rats; in the first hour after injection, 10 µg/kg amylin and 5 µg/kg sCT 
reduced food intake to a similar extent and there was no significant difference 
in the eating-inhibitory effect detectable at this time point (F (2,16) = 13.17, p 
>0.05). Two and four hours after injection, only sCT but not amylin reduced 
eating. In the APX rats (Figure 2B) neither peptide evoked a significant 
reduction of the cumulative food intake in the first two hours. However, there 
was a significant difference four hours after the injection between sCT and 
amylin, but not saline controls (one-way repeated-measures ANOVA and 
Bonferroni post-hoc analysis; F (2,12) = 7.112, p < 0.01). 
 
Experiment 3:Co-localization of cFos- and DBH- positive neurons in the AP 
and NTS  
One-way ANOVA followed by a Bonferroni post-hoc analysis revealed that 5 
µg/kg of sCT produced significantly more cFos-positive cells (F (2,14) = 
122.7, p<0.05) and neurons double-labeled for cFos and DBH than 10µg/kg of 
amylin (F (2,14) = 71.7, p<0.05) in the AP (Figure 4A). Relative co-activation 
was similar, with approximately 44% of the amylin-induced and 47% of the 
sCT-induced cFos-positive neurons being also positive for DBH; there was no 
difference between these percentages (t (5)= 0.7585, p=0.4823). Further, 
there was no significant difference in number of DBH-positive cells across the 
treatment groups (F (2,14) = 1.431, P=0.272; Figure 4A). 
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Compared to saline, both amylin and sCT treatment resulted in a significant 
increase in cFos in the NTS of sham rats (F (2,14) = 12.36, p<0.001; Figure 
4B). Amylin (10µg/kg) led to a higher number of double-stained neurons (F 
(2,14) = 14.53, p<0.05) and a greater number of DBH-positive cells than sCT 
(5µg/kg; F (2,14) = 12.45, p<0.01). Overall, the percentage of colocalization 
was much lower than in the AP. Neither amylin nor sCT induced cFos 
expression in the NTS of AP-lesioned rats (Figure 4C). There was no 
significant difference in the number of DBH-positive cells between the 
treatment groups (F= (2,10)=3.357, p = 0.0766). 
 
Experiment 4: Co-localization of cFos- and TPH-positive neurons in hindbrain 
nuclei 
Amylin (10 µg/kg) and sCT (5 µg/kg) significantly increased the number of 
cFos-positive cells in the AP compared to saline (one-way ANOVA and 
Bonferroni post-hoc analysis; F (2, 14) = 67.25, p<0.0001), however no TPH-
positive neurons were detected in either group (Figure 5A). Amylin (10 µg/kg) 
and sCT (5 µg/kg) significantly increased the number of cFos-positive cells in 
the NTS of sham-lesioned rats (F (2,14)=18.35, p= 0.0001, n=5-6 per group; 
Figure 5B). Amylin and sCT treatment did not significantly alter the number of 
TPH-positive cells in the NTS of sham rats, and there was no appreciable 
overlap in double-labeled neurons across the three groups. Following APX 
(Figure 5C), the number of amylin- and sCT-induced cFos-positive cells in the 
NTS was indistinguishable from saline-treated rats.  
 
One-way ANOVA followed by Bonferroni post-hoc analysis suggested that a 
constitutive amount of cFos, TPH and a low degree of co-localization (Table 
3) of these two markers seemed to be present in the dorsal and central raphe 
nuclei, independent of treatment and surgery (sham vs. APX).  
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Experiment 5: Co-localization of cFos- and DBH-positive neurons apposed to 
VGLUT2-positive boutons in the AP 
Using CM, rats treated with sCT exhibited a significantly greater number of 
cFos-positive cells in the AP, compared to amylin-treated rats (t (9) = 3.157, p 
= 0.0116; Figure 6A); this coincides with the results acquired with the 
standard LM method. Using CM analysis, amylin and sCT did not alter the 
number of DBH positive cells in the AP (t (9) = 0.3311, p= 0.7482; Figure 6B). 
There was a significant difference in the number of double-labeled cells 
between amylin and sCT (t (9) = 3.094, p= 0.0128) as shown in Figure 6C, but 
the percent co-localization did not differ between amylin and sCT. 
Furthermore, there was no significant difference in the total number of 
VGLUT2-positive boutons (t (9) = 2.082, p= 0.067; Figure 6D) or the number 
of VGLUT2-positive boutons per double-labeled cell (t (9) = 0.5655, p= 
0.5855; Figure 6E) when comparing sCT- and amylin-treated groups. In 
amylin-treated sham rats, an average of 94.6% of all cells co-expressing cFos 
and DBH were apposed to VGLUT2-positive boutons, versus a mean of 
95.2% for sCT; these percentages did not significantly differ (t (9) = 0.2411, 
p= 0.8149). 
 
Based on the Gunderson-Jensen estimator (Gundersen et al., 1999), using a 
smoothness constant of 1 for the AP, the ratio between mean CE2 and the 
observed relative variance CV2, was less than 0.5 for all the markers 
estimated, demonstrating that the sampling procedure contributed only little to 
the observed group variances. 
 
Experiment 6: Comparison of the two methods of quantification 
When comparing the results obtained with CM to those obtained with LM, we 
did not detect a significant difference in the percentage of cFos cells that were 
double-labeled for cFos and DBH following amylin (t (5)= 0.1353, p= 0.8977) 
or sCT treatment (t (4)= 0.131, p= 0.9021), as depicted in Figure 7A. 
However, the LM method appeared to underestimate the portion of DBH cells 
that co-express cFos, compared to CM, in both amylin- (t (5)= 3.496, p= 
0.0174) and sCT-treated groups (t (4)= 5.703, p= 0.0047; Figure 7B). 
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Discussion 
 
The AP is a critical brain area for the control of homeostatic nutrient handling. 
The AP relays information relating to gastric emptying, mediates the formation 
of conditioned taste aversion, and expresses receptors for many metabolic 
hormones including amylin, GLP-1, and ghrelin (Edwards et al., 1998; Fry & 
Ferguson, 2009; Punjabi et al., 2011; Zuger et al., 2013). The purpose of the 
present study was threefold: First, we characterized meal patterns in sham- 
and AP-lesioned rats under ad libitum and post-deprivation conditions. 
Second, we sought to clarify the role of the AP in sCT-induced anorexia over 
a range of doses, relative to amylin’s effect. Finally, we examined and 
compared the phenotype of hindbrain neurons expressing amylin- and sCT-
induced cFos, and thereby used for the first time the CM approach to quantify 
cells in the AP. 
 
Over the course of our experiments, and consistent with previous work done 
in our laboratory, it became evident that when using APX rats for behavioral 
experiments which involved 12-hour fasting, rats did not react the same way 
as their sham controls. APX rats had a long latency to eat and some didn’t 
start eating for up to 4 hours into the dark phase. Earlier work with AP-
lesioned rodents suggested that the AP plays a crucial role in the detection of 
inhibitory signals triggered by food or fluid ingestion, and that ingestive bouts 
increase in size after APX because the inhibitory feedback is blunted (Stricker 
et al., 1997). It has also been proposed that because total daily food intake is 
similar in control and APX rats, APX disrupts the short-term control of meal 
pattern but possibly not the long-term control of caloric intake in association 
with body weight maintenance (Ritter & Edwards, 1984). Consistent with 
these findings, our analysis of meal patterns showed that although APX and 
sham rats consumed comparable amounts of chow per day under ad libitum 
conditions, there were differences in how their meals were structured and how 
the two groups responded to a 12-hour light phase fast. Under ad libitum 
conditions, APX ate larger, but fewer meals compared to sham rats. Further, 
we observed that APX rats ingested a larger first meal after dark-onset than 
sham rats, but the latency to do so was much longer. After fasting the rats for 
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12 hours during the light phase, sham rats compensated by eating more food 
over the subsequent 24-h period than under ad libitum conditions. They did so 
by increasing their average meal size and reducing the latency to feed after 
the fast. In contrast, the meal profile in APX rats remained almost unaltered 
by the metabolic challenge; APX rats consumed even fewer meals than under 
ad libitum conditions and ate less over the subsequent 24 hours. Hence, APX 
rats appeared unaffected by the preceding caloric deficit. 
 
It was initially suggested that the disruption in ingestive patterns following AP 
lesions was a result of the loss of signals of gastric distention (Stricker et al., 
1997). Today we know that ablation of the AP not only thwarts a major relay 
station for vagal and splanchnic sensory information passing from the viscera 
to the brain, but also destroys several neuronal populations carrying receptors 
responsive to various hormones controlling food intake. Ablation of AP 
neurons prevents amylin-induced satiation thus inflating meal size (Lutz et al., 
1998; Reidelberger et al., 2002; Potes et al., 2010). The loss of AP neurons 
carrying GLP-1 receptors (Yamamoto et al., 2003), which likely constitute a 
neuronal population discrete from amylin-responsive neurons (Zuger et al., 
2013), is another potential contributor to the large extended meals observed 
following APX. The loss of a third receptor population could explain the 
increased latency to feed under both ad libitum and post-deprivation 
conditions. Ghrelin receptors are also present in the AP (Zigman et al., 2006) 
and APX was previously shown to blunt ghrelin’s orexigenic effect in rats at 
least under certain conditions (Gilg & Lutz, 2006). Further, ghrelin exerts a 
direct effect on the electrical activity of a subpopulation of AP neurons (Fry & 
Ferguson, 2009).  Ghrelin signaling in the AP might be critical for both normal 
meal initiation and for enhancing food seeking and consumption after a fast. 
We suggest here that the lack of ghrelin signaling might lead to the delayed 
initiation to feed in APX rats.  
 
In the second part of our studies, we found that, similar to amylin, an intact AP 
was necessary to produce sCT’s full anorectic action, confirming previous 
studies (Lutz et al., 2001). Results from the dose-response study showed that 
at higher doses, sCT is capable of reducing food intake to a certain extent in 
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APX rats. Thus, while sCT acting on the AP appears to be the primary route 
of action, we cannot rule out the possibility that sCT may also reduce food 
intake though an AP-independent mechanism or that some remaining intact 
AP neurons are sufficient to mediate some reduction in eating after higher 
doses of sCT. A recent study suggests that the ventral tegmental area (VTA), 
a key brain center for reward processing, not only expresses all components 
of the amylin receptor, but also seems to play a role in the direct mediation of 
the effects of peripheral sCT on food intake (Mietlicki-Baase et al., 2013); it 
was observed that local VTA administration of an amylin antagonist increased 
food intake and partly prevented the eating inhibitory effect of peripheral sCT. 
Therefore, in parallel to the immunohistochemical studies described here, we 
also analyzed an additional series of tissue sections for the colocalization of 
the enzyme catalyzing dopamine synthesis, tyrosine hydroxylase (TH) and 
cFos activation in AP- and sham-lesioned rats treated with either 10 µg/kg of 
amylin, 5 µg/kg of sCT or vehicle. Although TH-positive neurons were 
abundant in the VTA of all groups, no cFos was detected under our conditions 
(unpublished data). These data suggest that further investigation is required 
to determine the role of the VTA following peripheral treatment with amylin or 
sCT. 
    
Despite the use of equipotent eating-inhibitory doses, sCT treatment 
produced a significantly higher number of cFos-positive neurons in the AP 
than amylin 90 min after injection. However, no difference in cFos was 
observed at the level of the NTS. APX blocked all NTS cFos activation by 
both amylin and sCT, further substantiating the importance of the AP for 
sCT’s satiating action and the activation of secondary brain areas. Even when 
comparing amylin- and sCT-induced activation with the aid of confocal 
microscopy and stereological techniques—a much more precise method of 
quantification and visualization of activated neurons—the relative effect was 
similar. This quantitative difference was likely the result of sCT’s ability to bind 
irreversibly and with higher affinity to amylin binding sites.  
 
In addition to comparing cFos activation after amylin and sCT treatment, we 
also investigated if sCT recruited additional hindbrain neuronal populations. 
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We confirmed previously published results from our group using LM and 
found that approximately 50% of amylin-activated neurons in the AP are 
noradrenergic (Potes et al., 2010).  Consistent with increased cFos 
expression, a slightly larger total number of sCT-induced cFos neurons co-
expressed DBH, compared to amylin. Further, it has been suggested 
previously that an intact serotonergic system is necessary for calcitonin-
induced analgesia (Ormazabal et al., 2001). Because sCT also activates 
calcitonin receptors, we therefore sought to determine if this system plays a 
role in other actions, like the suppression of food intake. However, we 
observed almost no overlap between the expression of cFos and TPH in the 
AP, NTS, DR or CR. These findings support previous results suggesting that 
the serotonergic system does not seem to mediate amylin-induced satiation 
(Lutz et al., 1996; Brunetti et al., 2002), and further demonstrate that 
activation of these serotonergic neurons is not necessary for sCT to suppress 
eating.   
 
In the last part of our study, we employed confocal imaging and stereology 
(CM), to study neuronal activation patterns in the entire AP. Using this 
method, we determined the apposition of VGLUT2-positive boutons to amylin- 
and sCT-activated neurons. Further, we used this method to evaluate the co-
expression of amylin- and sCT-induced cFos and DBH labeling. A difference 
in the number of VGLUT2 boutons per activated neuron, which may suggest a 
difference in the excitatory drive to this population of AP neurons, could 
potentially underlie the stronger and in particular the longer inhibition of 
feeding observed after sCT, compared to amylin. However, we found that 
almost all (~95%) amylin- and sCT-activated neurons were in contact with 
VGLUT2 boutons, and we did not observe a difference between amylin and 
sCT in the number of VGLUT2 appositions per double-labeled neuron. These 
results suggest that, at least following acute treatment, there is no difference 
in glutamatergic apposition between neurons activated by amylin or sCT. We 
did not determine if chronic treatment of amylin or sCT would modify the 
glutamatergic drive of these populations.  
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The results from our current study underscore the role of the AP in controlling 
short-term food intake. The meal pattern analysis showed that a lesion of the 
AP disrupts the negative feedback signals controlling meal size and seems to 
affect the ability to compensate for an energy deficit following a fast. Further, 
we found that, like amylin, sCT requires an intact AP to produce its full effect 
on food intake and to induce cFos in the NTS. We observed that neither 
peptide induced cFos in TPH-expressing neurons in the NTS, DR, or CR, and 
detected no difference in the number of VGLUT2 boutons apposed to amylin- 
or sCT-activated neurons expressing DBH. Use of confocal microscopy 
confirmed that, like amylin, approximately 50% of sCT-activated neurons in 
the AP are noradrenergic. The phenotype of the remaining cFos-positive 
neurons in the AP remains to be defined. Our study demonstrates that the 
hindbrain mechanisms activated by amylin and its agonist sCT share many 
similarities; substantial differences, which could be due to an effect of sCT 
(but not amylin) on calcitonin receptors, were not observed.  
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Table 1. Immunohistochemical reagents 
 
 
 
Reagents Antigen/ 
conjugate 
Hos
t 
Type Source Catalog no. Dilution 
Primary cFos Rb polyclonal Calbioche
m 
PC38 1:1000
0 
Secondary Anti-rabbit 
IgG 
Dk Cy3-
labeled 
Jackson 711-165-
152 
1:400 
Secondary Anti-rabbit 
IgG 
Dk Biotinylate
d 
Jackson 711-065-
152 
1:400 
Primary DBH Ms monoclona
l 
Millipore MAB308 1:1000 
Secondary Anti-mouse 
IgG 
Dk Alexa488-
labeled  
Jackson 715-545-
150 
1:400 
Primary TPH Sh polyclonal Millipore AB1541 1:5000 
Secondary Anti-sheep 
IgG 
Dk Biotinylate
d 
Jackson 713-065-
003 
1:400 
Primary VGLUT2 Gp polyclonal Millipore AB5907 1:2000 
Secondary Anti-guinea 
pig 
Dk Alexa647-
labeled  
Jackson 706-605-
148 
1:400 
Immune-
peroxidase 
ABC system  Vectastain 
Elite ABC 
kit 
Vector PK-6100 1:400 
Chromagen DAB   Sigma D5637 1:20 
Peroxidase 
Substrate 
ImmPact 
NovaRed 
  Vector SK4805  
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Table 2. Mean ± SEM meal parameters measured in sham and APX rats 
under ad libitum conditions and following a 12-h light phase fast 
 
 
 
 Ad libitum Post-deprivation 
 
SHAM 
Mean ± 
SEM 
APX 
Mean ± 
SEM 
P values 
SHAM 
Mean ± 
SEM 
APX 
Mean ± 
SEM 
P values 
Total food 
intake/24 h 
(g) 
 
28.0  ± 0.7 28.1 ± 1.8 0.9438 31.4 ± 1 23.2 ± 2.7 0.0042 
Total meal 
number/24 h 
 
8.0  ± 0.4 5.9 ± 0.5 0.0014 7.7 ± 0.4 4.6 ± 0.3 <0.0001 
Average meal 
size (g) 
 
3.6 ± 0.2 5.0 ± 0.3 0.0007 4.3 ± 0.3 5.4 ± 0.5 0.0537 
Meal duration 
(min) 30.6  ± 2.9 41.5 ± 4.3 0.0375 37.2 ± 4.5 44.9 ± 4.2 0.2360 
First meal 
size (g) 2.7 ± 0.2 5.4 ± 0.5 <0.001 5.5 ± 0.7 5.2 ± 0.5 0.7456 
Inter-meal 
interval (min) 
 
65.8  ± 5.3 60.9 ± 6.9 0.5785 75.1 ± 6.1 82.3 ± 20.8 0.7099 
Latency to 
feed (min) 
 
10.3  ± 3.9 47.7 ± 13.3 0.0055 1.2 ± 0.3 
60.6 ± 
12.2 <0.0001 
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Table 3. Mean ± SEM number of cFos-positive, TPH-positive, and 
double-labeled cells in the Dorsal and Central Raphe nuclei of sham and 
APX rats after treatment with vehicle, amylin (10 µg/kg) or sCT (5 µg/kg).  
 
 
 
Dorsal Raphe 
nucleus 
 
SHAM 
 APX 
Vehicle 
Mean ± 
SEM 
Amylin 10 
µg/kg 
Mean ± 
SEM 
sCT 5 µg/kg 
Mean ± 
SEM 
Vehicle 
Mean ± 
SEM 
Amylin 10 
µg/kg 
Mean ± 
SEM 
sCT 5 µg/kg 
Mean ± 
SEM 
cFos-positive 9.6 ± 4.3 20.3 ± 5.2 7.2 ± 2.4 6.5 ± 2.5 19.6 ± 6.6 12.0 ± 7.4 
Double labeled 
(cFos+TPH) 2.4 ± 1.3 8.2 ± 3.0 1.8 ± 0.6 0.9 ± 0.5 4.9 ± 2.4 4.5 ± 3.1 
TPH-positive 100.6 ± 5.7 117.7 ± 12.1 114.6 ± 22.7 116.4 ± 13.6 109.0 ± 13.2 101.9 ± 13.1 
 
 
 
Central Raphe 
nucleus 
 
SHAM 
 APX 
Vehicle 
Mean ± 
SEM 
Amylin  
10 µg/kg 
Mean ± 
SEM 
sCT  
5 µg/kg 
Mean ± 
SEM 
Vehicle 
Mean ± 
SEM 
Amylin  
10 µg/kg 
Mean ± 
SEM 
sCT  
5 µg/kg 
Mean ± 
SEM 
cFos-positive 4.4 ± 2.4 8.1 ± 3.0 3.5 ± 1.2 4.0 ± 1.8 10.7 ± 4.7 7.5 ± 3.0 
Double labeled 
(cFos+TPH) 1.1 ± 0.7 2.4 ± 0.8 1.6 ± 0.8 0.4 ± 0.1 2.5 ± 1.2 1.1 ± 0.6 
TPH-positive 49.6 ± 7.5 57.1 ± 3.9 53.6 ± 5.7 49.6 ± 2.9 54.9 ± 1.8 49.7 ± 3.7 
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Figure legends 
 
 
Figure 1. Amylin and sCT lead to a dose-dependent reduction in 
cumulative food intake; sCT’s effect was more potent and longer lasting. 
Mean ± SEM cumulative food intake 1, 2, 4, and 24 hours after injection of 
vehicle, amylin (1, 5, or 10 µg/kg; A, B) or sCT (1, 5, or 10 µg/kg; C, D) in 
sham-lesioned (A, C) and APX rats (B, D). * significantly different from vehicle 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; °°° significantly different from amylin (1 
µg/kg) p ≤ 0.001 
 
 
Figure 2. Amylin (10 µg/kg) and sCT (5 µg/kg) reduced cumulative food 
intake similarly in sham rats in the first hour after injection compared to 
vehicle. Neither amylin nor sCT reduced eating in APX rats compared to 
the respective control. 
Mean ± SEM cumulative food intake 1, 2, and 4 hours after injection of 
vehicle, amylin (10 µg/kg) or sCT (5 µg/kg) in sham-lesioned (A) and APX rats 
(B). ** significantly different from vehicle p ≤ 0.01, *** p ≤ 0.001; °° significantly 
different from amylin (10 µg/kg) p ≤ 0.01 
 
Figure 3. Representative images showing co-localization of cFos- (red nuclei) 
and DBH- expressing (green cell bodies) neurons in the AP of sham rats after 
(A) saline, (B) amylin (10 µg/kg), (C) sCT (5 µg/kg) treatment. Representative 
images showing minimal co-localization of cFos- (black nuclei) and TPH-
expressing (orange cell bodies) neurons in the dorsal raphe nucleus of sham 
(D) and APX (E) rats treated with 5 µg/kg of sCT. Representative images 
showing the co-localization of cFos (red nuclei), DBH (green cell bodies), and 
VGLUT2 (cyan boutons) in the AP of sham rats treated with 10 µg/kg amylin 
(F) or 5 µg/kg of sCT (G). High-magnification confocal scan of AP from sham 
rat treated with 5 µg/kg of sCT showing example of VGLUT2 bouton (white 
arrow) apposed to a neuron co-expressing cFos and DBH (H).  
 
Figure 4. Amylin and sCT-induced cFos co-localizes with DBH-positive 
neurons in the AP and NTS of sham rats. 
Mean ± SEM number of cFos-positive, DBH-positive, and double-labeled cells 
in the AP (A) and NTS (B) of sham rats, and the NTS of APX rats (C) after 
treatment with vehicle, amylin (10 µg/kg) or sCT (5 µg/kg). ** significantly 
different from vehicle p ≤ 0.01, *** p ≤ 0.001; ° significantly different from 
amylin (10 µg/kg) p ≤ 0.05 
 
 
Figure 5. Amylin and sCT-induced cFos does not co-localize with TPH-
positive neurons in the AP and NTS of sham rats. 
Mean ± SEM number of cFos-positive, TPH-positive, and double-labeled cells 
in the AP (A) and NTS (B) of sham rats, and the NTS of APX rats (C) after 
treatment with vehicle, amylin (10 µg/kg) or sCT 5 (5 µg/kg). ** significantly 
different from vehicle p ≤ 0.01, *** p ≤ 0.001 
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Figure 6. Using CM, approximately 50% of cFos-positive cells were also 
DBH-positive after amylin (10 µg/kg) and sCT (5 µg/kg) and there was a 
similar apposition of VGLUT2-positive boutons in amylin- (10 µg/kg) and 
sCT- (5 µg/kg) treated sham rats. 
Mean ± SEM unbiased estimation of the number of cFos positive cells (A), 
DBH-positive cells (B) and cFos and DBH double-labeled cells (C) in the 
entire AP of sham rats treated with 10 µg/kg amylin or 5 µg/kg sCT, as 
quantified using the CM method. Mean ± SEM unbiased estimation of the total 
number of VGLUT2-positive boutons apposed to neurons co-expressing cFos 
and DBH (D) and average number of VGLUT2 positive boutons per double-
labeled cell (E) in the entire AP of sham rats treated with 10 µg/kg amylin or 5 
µg/kg sCT. + significantly different from amylin (10 µg/kg) p ≤ 0.05 
 
 
Figure 7. Compared to CM, LM underestimated the degree of DBH-
expressing neurons that also express cFos, but not cFos-expressing 
neurons that also express DBH. Mean ± SEM percentage of total cFos-
positive cells that co-localize with DBH (A) and the percentage of total DBH-
positive cells that co-localize with cFos (B) in the AP of sham rats treated with 
10 µg/kg amylin or 5 µg/kg sCT, as calculated using LM (light microscopical 
manual counting quantification) and CM (confocal stereological quantification) 
methods of quantification. * significantly different from LM p ≤ 0.05, ** p ≤ 0.01 
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List of Abbreviations 
 
 
AP    Area postrema 
APX    Area postrema lesion/lesioned 
CM    Confocal stereological quantification method 
CR    Central raphe nucleus 
DBH    Dopamine-beta-hydroxylase 
DR    Dorsal raphe nucleus 
LM    Light microscopical manual counting method 
NDS    Normal donkey serum 
NGS    Normal goat serum 
NTS    Nucleus of the solitary tract 
PB    Phosphate buffer 
sCT    Salmon calcitonin 
TPH    Tryptophan-hydroxylase 
VGLUT2   Vesicular glutamate transporter 2 
VTA    Ventral tegmental area !
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